S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
Log in

NASDAQ:CDLX - Cardlytics Stock Price, Forecast & News

$57.69
-0.65 (-1.11 %)
(As of 12/11/2019 04:00 PM ET)
Today's Range
$57.00
Now: $57.69
$58.30
50-Day Range
$37.28
MA: $50.38
$64.15
52-Week Range
$9.80
Now: $57.69
$65.43
Volume188,356 shs
Average Volume356,861 shs
Market Capitalization$1.32 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.71
Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. Read More…

Industry, Sector and Symbol

Industry Computer programming, data processing, & other computer related
Sub-IndustryN/A
SectorBusiness Services
Current SymbolNASDAQ:CDLX
CUSIPN/A
Phone888-798-5802

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$150.68 million
Book Value$2.56 per share

Profitability

Net Income$-53,040,000.00

Miscellaneous

EmployeesN/A
Market Cap$1.32 billion
Next Earnings Date3/3/2020 (Estimated)
OptionableNot Optionable

Receive CDLX News and Ratings via Email

Sign-up to receive the latest news and ratings for CDLX and its competitors with MarketBeat's FREE daily newsletter.


Cardlytics (NASDAQ:CDLX) Frequently Asked Questions

What is Cardlytics' stock symbol?

Cardlytics trades on the NASDAQ under the ticker symbol "CDLX."

How were Cardlytics' earnings last quarter?

Cardlytics Inc (NASDAQ:CDLX) issued its quarterly earnings results on Tuesday, November, 12th. The company reported $0.03 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.28) by $0.31. The company earned $56.42 million during the quarter, compared to analysts' expectations of $50.02 million. Cardlytics had a negative net margin of 17.01% and a negative return on equity of 44.53%. The firm's revenue was up 63.2% compared to the same quarter last year. During the same quarter last year, the company posted ($0.15) EPS. View Cardlytics' Earnings History.

When is Cardlytics' next earnings date?

Cardlytics is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Cardlytics.

What guidance has Cardlytics issued on next quarter's earnings?

Cardlytics updated its FY 2019 After-Hours earnings guidance on Monday, November, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $$196-200 million, compared to the consensus revenue estimate of $$190.49 million.

What price target have analysts set for CDLX?

7 equities research analysts have issued twelve-month target prices for Cardlytics' stock. Their forecasts range from $26.00 to $75.00. On average, they expect Cardlytics' share price to reach $46.50 in the next year. This suggests that the stock has a possible downside of 19.4%. View Analyst Price Targets for Cardlytics.

What is the consensus analysts' recommendation for Cardlytics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardlytics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cardlytics.

Has Cardlytics been receiving favorable news coverage?

News headlines about CDLX stock have trended positive on Wednesday, InfoTrie reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Cardlytics earned a media sentiment score of 2.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future. View News Stories for Cardlytics.

Are investors shorting Cardlytics?

Cardlytics saw a decline in short interest during the month of November. As of November 29th, there was short interest totalling 3,230,000 shares, a decline of 5.8% from the November 14th total of 3,430,000 shares. Based on an average trading volume of 559,500 shares, the short-interest ratio is presently 5.8 days. Currently, 14.7% of the company's stock are short sold. View Cardlytics' Current Options Chain.

Who are some of Cardlytics' key competitors?

What other stocks do shareholders of Cardlytics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardlytics investors own include Caterpillar (CAT), Alibaba Group (BABA), Okta (OKTA), Trade Desk (TTD), salesforce.com (CRM), Shopify (SHOP), Square (SQ), Advanced Micro Devices (AMD), Baidu (BIDU) and Coupa Software (COUP).

Who are Cardlytics' key executives?

Cardlytics' management team includes the folowing people:
  • Mr. Scott D. Grimes, Co-Founder, CEO & Director (Age 56)
  • Ms. Lynne Marie Laube, Co-Founder, COO & Director (Age 49)
  • Mr. David Evans, CFO & Head of Corp. Devel.
  • Mr. Sathish Gaddipati, Chief Technology Officer (Age 52)
  • Mr. Kirk L. Somers, Chief Legal & People Officer (Age 54)

When did Cardlytics IPO?

(CDLX) raised $76 million in an initial public offering (IPO) on Friday, February 9th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.

Who are Cardlytics' major shareholders?

Cardlytics' stock is owned by many different of institutional and retail investors. Top institutional investors include State Street Corp (1.08%), Millennium Management LLC (0.82%), Kornitzer Capital Management Inc. KS (0.81%), JS Capital Management LLC (0.55%), Tygh Capital Management Inc. (0.53%) and Hancock Whitney Corp (0.49%). Company insiders that own Cardlytics stock include Aimia Inc, Bryce Youngren, Clifford Sosin, David Leslie Adams, David Thomas Evans, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Polaris Venture Management Co, Scott D Grimes and Tony Weisman. View Institutional Ownership Trends for Cardlytics.

Which major investors are selling Cardlytics stock?

CDLX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Tygh Capital Management Inc. and CIBC Private Wealth Group LLC. Company insiders that have sold Cardlytics company stock in the last year include Aimia Inc, Bryce Youngren, David Leslie Adams, David Thomas Evans, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Polaris Venture Management Co, Scott D Grimes and Tony Weisman. View Insider Buying and Selling for Cardlytics.

Which major investors are buying Cardlytics stock?

CDLX stock was acquired by a variety of institutional investors in the last quarter, including JS Capital Management LLC, Hancock Whitney Corp, Kornitzer Capital Management Inc. KS, Covey Capital Advisors LLC, Squarepoint Ops LLC, Stifel Financial Corp, Columbus Circle Investors and D.A. Davidson & CO.. Company insiders that have bought Cardlytics stock in the last two years include Clifford Sosin, David Thomas Evans and Scott D Grimes. View Insider Buying and Selling for Cardlytics.

How do I buy shares of Cardlytics?

Shares of CDLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cardlytics' stock price today?

One share of CDLX stock can currently be purchased for approximately $57.69.

How big of a company is Cardlytics?

Cardlytics has a market capitalization of $1.32 billion and generates $150.68 million in revenue each year. The company earns $-53,040,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis. View Additional Information About Cardlytics.

What is Cardlytics' official website?

The official website for Cardlytics is http://www.cardlytics.com/.

How can I contact Cardlytics?

Cardlytics' mailing address is 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308. The company can be reached via phone at 888-798-5802 or via email at [email protected]


MarketBeat Community Rating for Cardlytics (NASDAQ CDLX)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  159 (Vote Outperform)
Underperform Votes:  204 (Vote Underperform)
Total Votes:  363
MarketBeat's community ratings are surveys of what our community members think about Cardlytics and other stocks. Vote "Outperform" if you believe CDLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDLX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel